INFLAMMATION AND COUNTER-REGULATORY LIPID MEDIATORS
===================================================

The inflammatory response is necessary for effective host defense, although it must eventually dissipate to ensure tissue homeostasis and avoid pathologic conditions such as abscess formation, scarring, fibrosis, and eventual organ failure ([@B70]). Indeed, compromised resolution has been proposed as an underlying mechanism in many prevalent chronic diseases such as arthritis, diabetes, and atherosclerosis ([@B132]; [@B87]). It is now recognized that the resolution of inflammation is a dynamically regulated process orchestrated by mediators that play important counter-regulatory roles including cytokines, chemokines, and lipid mediators such as the lipoxins (LXs), resolvins, and protectins ([@B127]). These mediators reduce vascular permeability and inhibit polymorphonuclear cell (PMN) recruitment, while promoting recruitment of monocytes and stimulating efferocytosis ([@B132]). It has also been proposed that pro-resolving lipids stimulate lymphatic drainage of leukocytes ([@B7]). Interestingly, the signaling pathways initially inducing prostaglandin (PG)E~2~ and PGD~2~ formation and thus the onset of inflammation, may actively switch the production of lipid mediators from pro-inflammatory to pro-resolving by inducing 5-lipoxygenases (LO) necessary for production of LXs, protectins, and resolvins ([@B131]). In this way physiological inflammation programs its own resolution and promotes tissue homeostasis ([@B73]).

LIPOXINS
========

The LXs are produced endogenously at sites of inflammation as counter-regulatory lipid mediators with anti-inflammatory, pro-resolving, and anti-fibrotic bioactions ([@B132]; [@B87]). LXs are typically generated by transcellular metabolism between neutrophils, platelets, and resident tissue cells, such as epithelial cells ([@B72]; [@B126]), through the sequential action of 5-LO and either 12-LO or 15-LO ([@B125]; [@B103]). LXs limit leukocyte chemotaxis ([@B71]) and activation of neutrophils and eosinophils ([@B11]), while stimulating Mφ efferocytosis of apoptotic cells ([@B44]; [@B93]; [@B115]). Lipoxin A~4~ (LXA~4~) and its positional isomer lipoxin B~4~ (LXB~4~) are the principal LX species found in mammals. Although the LXB~4~ receptor remains to be identified, the LXA~4~ receptor FPR2/ALX is expressed on cells of diverse lineage, including fibroblasts ([@B157]), renal mesangial cells ([@B90]; [@B92]), and epithelial cells ([@B95]). LXs are protective in several experimental models of disease, e.g., inflammatory bowel diseases ([@B40]), periodontal disease ([@B124]; [@B60]; [@B59]), and cardiovascular disease ([@B125]). LXs have also been reported to act as vasodilators ([@B150]) and may reprogram Mφs from a classically activated (M1) phenotype to a spectrum of alternative activation ([@B93]). The bioactions of LXs are summarized in **Table [1](#T1){ref-type="table"}**. The impact of LXs in maintaining the exquisite equilibrium between effective host defense and homeostasis is remarkably illustrated by the fact that over production of LXs may compromise host defense to pathogens. In the case of *Mycobacterium tuberculosis (M.tb),* increased LXA~4~ production is associated with decreased TNF-α activity and results in an inadequate inflammatory response ([@B147]). Conversely, LXA~4~ increases survival rate in *Toxoplasma gondii*infection where a compromised immune response due to diminished LO activity and LX biosynthesis is detrimental ([@B2]).

###### 

Lipoxin induced bioactions.

  Cell type                       Bioactions*in vitro*
  ------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Monocytes                       Stimulate chemotaxis and adhesion without causing ROS production ([@B86])
  Macrophages                     Stimulate efferocytosis while reducing inflammatory cytokine secretion (IFN-γ and IL-6) and increasing pro-resolving cytokine secretion (IL-10) ([@B93]; [@B123])
                                  Switch Mφ phenotype from inflammatory to pro-resolving
  PMN                             Inhibit chemotaxis, adhesion, and transmigration ([@B25]).
                                  Inhibit pro-inflammatory cytokine secretion ([@B57])
                                  Inhibit ROS production ([@B75]; [@B18])
                                  Enhance CCR5 expression on apoptotic PMN ([@B4])
                                  Attenuate P-selectin-mediated PMN--endothelial cell interactions ([@B102])
  DCs                             Regulated as monocytes differentiate into DCs ([@B161])
                                  Trigger SOCS-2 expression ([@B83])
  Eosinophils                     Inhibit chemotaxis, IL-5, and eotaxin secretion ([@B137]; [@B11]; [@B74])
  Platelet                        Inhibit *Porphyromonas gingivalis*-induced aggregation ([@B18])
  T cells                         Inhibit anti-CD3 Ab induced TNF-α ([@B3])
  NK-cells                        Block cytotoxicity ([@B3], [@B4])
  PBMC                            Inhibit anti-CD3 Ab induced TNF-α ([@B3])
  Endothelium                     Inhibit P-selectin mobilization ([@B122])
                                  Upregulate IL-10 while inhibiting LTD~4~ and VEGF stimulated proliferation and angiogenesis ([@B10])
  Epithelium                      Inhibit TNF-α induced IL-8 ([@B14])
                                  Inhibit epithelial to mesenchymal transition ([@B159])
  Fibroblasts                     Inhibit proliferation ([@B157])
                                  Inhibit IL-1β induced IL-6, IL-8, and MMP-3 ([@B136])
  Mesangial cells                 Inhibit inflammatory cytokine production ([@B158]), proliferation and cell cycle progression ([@B9]; [@B2], [@B1]; [@B6], [@B8]) as well as ROS production ([@B91])
  GI epitlelium (enterocytes)     Antagonize TNF-α stimulated neutrophil-enterocyte interactions *in vitro* and attenuate TNF-α chemokine release and colonocyte apoptosis in human intestinal mucosa *ex vivo* ([@B45])
                                  Inhibit TNF-α induced IL-8 ([@B43])
  Hepatocytes                     Reduce PPARα and CINC-1 expression ([@B109])
  Astrocytoma cells               Inhibit IL-1β induced IL-8 and ICAM-1 expression ([@B30])
  **LXB~4~ and LXB~4~-analogs**   
  Monocytes                       Stimulate monocytes recruitment, chemotaxis and adherence without causing ROS production ([@B86])
                                  Increase adherence of undifferentiated THP-1 to laminin ([@B84])
  PBMC                            Inhibit anti-CD3 Ab induced TNF-α ([@B3])
  PMN                             Inhibit PMN migration across endothelium (HUVEC monolayer; [@B84])
                                  Attenuate P-selectin-mediated PMN--endothelial cell interactions ([@B102])
  NK cells                        Inhibit cytotoxicity ([@B113])

LIPOXIN RECEPTORS AND SYNTHETIC LIPOXIN ANALOGS
===============================================

The principal LXA~4~ receptor is FPR2/ALX, which has been identified and cloned in numerous cell types, including monocytes and Mφs ([@B85]), T cells ([@B3]), synovial fibroblasts ([@B136]), renal mesangial cells ([@B90]), and enterocytes ([@B49]). In contrast to conventional GPCRs, which typically show very specific ligand binding, the FPR2/ALX receptor binds pleiotropic ligands, both lipids and small peptides, such as acute phase proteins ([@B24]), and may elicit ligand-dependent pro-inflammatory or anti-inflammatory responses ([@B25]; [@B87]). [@B67] recently found that LXA~4~ also interacts with another G-protein coupled receptor, namely GPR32.

LXA~4~ undergoes rapid inactivation *in vivo*, primarily by PG dehydrogenase-mediated oxidation and reduction ([@B130]) and efforts have been made to design chemically stable LX analogs. Because the three-dimensional molecular structure of the FPR2/ALX receptor is as of yet unknown, designing LXA~4~ analogs is based on experimentally discovered structure/function relationship of LXA~4~. The LXA~4~ molecule can be considered in three regions; the lower chain, the upper chain, and the tetraene side chain ([@B37]). The first generation LXA~4~ analogs carry modifications in the lower alkyl chain, to increase metabolic stability and prevent oxidation ([@B28]). The second generation analogs are collectively referred to as 3-oxa-LXA~4~ and were constructed carrying modifications in the upper chain ([@B107]), replacing the C~3~ methylene group with an oxygen molecule ([@B50]). The third generation LXA~4~ analogs are characterized by replacement of the triene structure with a benzene ring ([@B99]; [@B108]). Importantly, the *o*-\[9, 12\]-Benzo-15-epi-LXA~4~ has been shown to activate the FPR/ALX receptor in a similar manner to native LXA~4~, using an engineered β-arrestin system ([@B140]).

RESOLVINS, PROTECTINS, AND MARSEINS
===================================

Resolvins, protectins, and maresins are pro-resolving lipids discovered by [@B128] through sophisticated lipidomic analysis of resolution phase exudates in the murine dorsal air pouch model. Resolvins may be divided into the E series (RvEs) and D series (RvDs), which are generated from eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), respectively, the most common forms of ω-3 PUFA. Similarly, protectins and maresins are generated from DHA. Like the LXs, resolvins are generated in a transcellular manner by the sequential action of LO. Protectins and maresins on the other hand are generated by single cells, but also through the action of LO. In neutrophils RvE1 has been shown to bind the GPCR LTB~4~ receptor BLT1 with a K~*d*~ of 45 nM ([@B8]), whereas in Mφ and dendritic cells RvE1 bind ChemR23 with a K~*d*~ of 11.3 ± 5.4 nM and B~max~ indicating approximately 4,200 binding sites per cell ([@B7]; [@B65]). RvD1 has also been reported to interact both with FPR2/ALX and GPR32 in phagocytes ([@B67]). As of yet it is not entirely clear which receptor the protectins and maresins act through, although PD1 has a high affinity surface binding site on human PMN and retinal pigment epithelium cells ([@B12]). Resolvins, protectins, and maresins all display potent anti-inflammatory and pro-resolving effects inhibiting production of pro-inflammatory mediators, regulating neutrophil trafficking and promoting efferocytosis ([@B123]; [@B127]). The effects of these lipid mediators are summarized in **Table [2](#T2){ref-type="table"}**.

###### 

Resolvin, protectin, and maresin induced bioactions.

  Cell type          Bioactions *in vitro*
  ------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------
  Macrophages        Stimulates efferocytosis while reducing IFN-γ and IL-6 ([@B123])
  PMN                Decreases transendothelial and epithelial migration ([@B20])
                     Stimulates L-selectin shedding, while reducing CD18 expression and inhibiting PMN rolling *in vivo* ([@B33])
                     Attenuates BLT1 depended TNF-α and NF-κB activation ([@B8])
                     Enhances CCR5 expression on apoptotic PMN ([@B4])
  Dendritic cells    Inhibits migration ([@B6])
                     Reduces IL-12 production from DCs stimulated with pathogen extract ([@B6])
  Platelets          Disruptes platelet aggregation ([@B33]; [@B41])
  **Resolvin D1**    
  Microglia cells    Inhibits IL-1β expression ([@B129])
  **Protectin D1**   
  PMN                Enhances CCR5 expression on apoptotic PMN ([@B4])
  Mφ                 Stimulates efferocytosis while reducing IFN-γ ([@B123])
  T cell             Promotes apoptosis, inhibits TNF-α and IFN-γ ([@B5])
  Glia cells         Reduces IL-1β-induced NF-κB activation and COX2 expression ([@B89]), reduces amyloid β-42-induced nerotoxicity, promotes amyloid β-induced apoptosis ([@B80])
  Epithelium         Protects from apoptosis induced by oxidative stress ([@B94])
  **Maresin 1**      
  Macrophage         Stimulates efferocytosis ([@B133])

INFLAMMATION AND TYPE 2 DIABETES MELLITUS
=========================================

Diabetes mellitus (DM) is a serious metabolic disorder of glucose homeostasis reflecting destruction of the β-cells of the pancreas and subsequent lack of insulin production (type 1 DM, T1DM) or decreased target organ sensitivity to insulin and β-cell dysfunction (type 2 DM, T2DM). T2DM is defined as having a fasting plasma glucose ≥7.0 mmol/l and affects over 90% of diabetics, or an estimated 285 million people globally ([@B29]). T2DM imposes significant socioeconomic burdens through its many diabetes-associated complications. These can be divided into microvascular complications \[diabetic nephropathy (DN), neuropathy, and retinopathy\] and macrovascular complications \[atherosclerosis, ischemic heart disease, stroke, and peripheral vascular disease often resulting in amputations\] ([@B155]). Risk factors of T2DM include genetic preposition, ethnicity, high blood pressure, and high cholesterol, but obesity is frequently cited as the primary cause.

The role of inflammation in diabetes is becoming more evident and elevated circulating interleukin (IL)-1β, IL-6, and C-reactive protein (CRP) are predictive of T2DM ([@B96]; [@B32]; [@B34]). These inflammatory markers are primarily derived from the adipose tissue and the liver. The hypothesis that the pathogenesis of T2DM reflects an inflammatory disorder is supported by preclinical studies and clinical trials using anti-inflammatory agents ([@B34]). Examples of these include IL-1β receptor blockers, anti-TNF-α and IL-6 therapies, as well as the use of salsalate. We will now briefly discuss current attempts to use anti-inflammatory therapeutics to attenuate the pathology of diabetes.

Interleukin-1β is a key regulator of inflammation both in T1DM and T2DM and has been shown to induce pancreatic β-cell apoptosis and exacerbate the systemic inflammation associated with diabetes, for instance by augmenting adipocyte TNF-α and IL-6 production ([@B1]). Patients with T2DM display increased IL-1β levels ([@B13]), while its naturally occurring IL-1 receptor antagonist (IL-1Ra) is diminished ([@B88]). Interest has been directed toward using IL-1Ra as a therapeutic in T2DM. Clinical trials show that the IL-1Ra anakinra improves glycemia and β-cell secretory functions, while attenuating systemic inflammation ([@B34]). For instance, anakinra administered over a 13-week period in T2DM patients increased insulin production, while glycosylated hemoglobin, i.e., HbA1c and the inflammatory marker CRP were significantly reduced ([@B69]). The limitation with IL-1Ra lies in its short half-life, but successful attempts have been made to increase its stability by fusing IL-1Ra with peptides such as human serum albumin (HLA) or elastin-like polypeptides (ELPs), although these compounds remain to be tested in diabetic models ([@B1]).

TNF-α is also implicated in the pathogenesis of insulin resistance (IR) and its expression correlates with reduced insulin-stimulated glucose disposal ([@B62]). TNF-α is elevated both in obese rodents ([@B149]) and obese humans ([@B55]; [@B62]) and furthermore decreases upon weight loss ([@B63]). TNF-α^--\ /\ --^ *ob/ob*mice have significantly improved insulin sensitivity ([@B149]) and obese mice lacking the TNF-α receptor are protected from high fat diet induced IR ([@B119]). However, in humans TNF-α neutralizing antibodies does not appear to improve insulin sensitivity in obese subjects ([@B97]; [@B120]). Nevertheless, TNF-α blockers are often used to treat rheumatoid arthritis (RA) and it was recently reported that obese RA patients receiving TNF-α blockers displayed improved fasting glucose and increased circulating adiponectin levels ([@B139]), possibly warranting more studies in the field. IL-6 is also an important inflammatory mediator in diabetes and increased levels correlate with IR ([@B110]), although it appears to have a dual role. Whereas IL-6 causes IR in adipocytes ([@B121]) and anti-IL-6 therapy over a 6 month period diminished HbA1c in diabetic RA patients ([@B98]), the IL-6 derived from skeletal muscle during exercise appears beneficial ([@B104]). The use of anti-IL-6 blockers as an anti-inflammatory therapeutic in diabetes has therefore been debated. Salsalate on the other hand is a very interesting drug in the context of diabetes and has been shown to reduce CRP, FFA, and triglycerides while increasing insulin sensitivity and adiponectin levels ([@B66]; [@B46]). Salsalate may, however, cause gastric irritation and should be used with caution in pregnancy ([@B148]; [@B27]). Collectively these studies indicate the potential of using anti-inflammatory therapeutics to attenuate T2DM.

RESOLUTION OF ADIPOSE INFLAMMATION IN TYPE 2 DIABETES MELLITUS
==============================================================

There is a growing appreciation that adipose tissue is not merely an insulating energy store but is actually an endocrine organ regulating appetite, glucose and lipid metabolism, blood pressure, inflammation, and immune function ([@B64]). Adipose tissue has been shown to play a particularly important role in the systemic inflammation associated with obesity, IR, and diabetes. Factors such as prolonged obesity or aging cause a state of systemic low-grade inflammation, which induces monocyte recruitment to the adipose tissue. Adipose tissue is a source of pro-inflammatory cytokines and adipose tissue Mφ (ATM) derived TNF-α, IL6, and IL-1β contribute to adipose IR and exacerbates systemic inflammation ([@B82]). Promoting resolution of adipose inflammation would likely be a beneficial therapeutic approach, reducing the risk of developing obesity-associated complications, such as IR and T2DM ([@B34]).

Given the spectrum of anti-inflammatory and pro-resolution bioactions of LXs and other counter-regulatory lipid mediators, these may provide a potential intervention to attenuate adipose inflammation ([@B47]). We recently reported a role of LXA~4~ in adipose inflammation, culturing adipose explants of aging mice as an *ex vivo* model of adipose inflammation ([@B19]). We confirmed that LXA~4~ increased expression of critical components of insulin sensitivity, including the glucose transporter GLUT-4 and IRS-1, consistent with restoring insulin sensitivity in the tissue. Furthermore, LXA~4~ decreased IL-6 secretion while increasing production of the pro-resolving IL-10, suggesting that LXA~4~ acted in a pro-resolving manner ([@B19]). Indeed, IL-10 inversely correlates with T2DM and has been shown to inhibit IL-6-induced IR, attenuate MCP-1 secretion, and promote GLUT-4 and IRS-1 expression ([@B81]; [@B47]). The study also demonstrated that LXA~4~ partially rescued MΦ-inhibited adipose glucose uptake *in vitro* ([@B19]). Inflammatory MΦs are a key component of augmented adipose IR ([@B82]; [@B29]; [@B138]). Importantly, LXA~4~-mediated reversal of insulin desensitization correlated with restored adipose Akt activation, which is necessary for translocation of the glucose sensitizing GLUT-4 receptor from the cytosol to the plasma membrane ([@B19]). Interestingly, RvD1 also increased insulin-stimulated pAkt in adipose tissue of obese *db/db* mice ([@B51]). Furthermore, LXA~4~ inhibited MΦ TNF-α production, which is an important cytokine previously demonstrated to inhibit adipose glucose uptake *in vitro* ([@B42]). LXA~4~ also inhibited MCP-1 secretion, though the importance of MCP-1 in adipose inflammation has been debated ([@B22]; [@B56]). The reduction of inflammatory cytokines may suggest that LXA~4~ promoted restoration of insulin sensitivity by altering MΦ phenotype toward resolution. Finally, LXA~4~ also appeared to have a direct impact on adipocytes as it rescued TNF-α-induced desensitization to insulin-stimulated Akt activation, which also correlated with increased GLUT-4 translocation.

The beneficial effects of ω-3 PUFA, RvE1, and PD1 have also been shown in *ob/ob* mice ([@B48]). Both ω-3 PUFA enriched diet and intraperitoneal injections of RvE1 increased expression of genes involved in glucose transport (GLUT-4) and insulin signaling (IRS-1), as well as genes involved in insulin sensitivity (PPARγ). Similar to ω-3 PUFA, RvE1 increased adiponectin levels, as did PD1 when incubated with adipose explants from *ob/ob* mice ([@B48]). Additional studies show that RvD1 decrease accumulation of ATMs and improve insulin sensitivity while reducing fasting blood glucose in *db/db* diabetic mice ([@B51]). Interestingly, the total number of ATMs remained unaltered with RvD1 treatment, but the ratio of M2:M1 increased. The number of adipose crown like structures (CLS) in obese animals was also reduced by 50--60% ([@B51]) and RvD1 significantly increased circulating adiponectin and adipose phosphorylation of AMPK. The study also reports diminished IL-6 secretion ([@B51]), which has previously been shown to suppress adiponectin in 3T3-L1 adipocytes ([@B38]) and may explain the restored adiponectin levels, which in turn have been shown to increase insulin sensitivity ([@B68]; [@B58]).

INFLAMMATION AND DIABETIC NEPHROPATHY
=====================================

Diabetic nephropathy presents a particularly important problem as it develops in 25--40% of diabetic patients and is the major cause of end-stage kidney disease ([@B117]). DN is a type of chronic kidney disease (CKD) rising in prevalence in concert with chronic DM in susceptible individuals. In addition to being the leading cause of renal failure, T2DM is also an independent risk factor in the development of cardiovascular disease ([@B142]). DN reflects the convergence of inflammatory, metabolic, and hemodynamic factors. Inflammation causes glomerulosclerosis, tubular atrophy, damage to renal vasculature, and fibrosis ([@B39]). Renal matrix accumulation arises in response to paracrine and autocrine mediators produced by resident and infiltrating cells, such as mesangial cells and Mφs.

Promoting inflammatory resolution is likely an attractive approach when trying to prevent renal fibrosis and CKD ([@B17]). The mechanisms by which resolution of renal inflammation occurs naturally and how they are subverted in disease are only beginning to be understood. Important components include efferocytosis of apoptotic cells and a change of the cytokine milieu from pro-inflammatory to anti-inflammatory/pro-resolving ([@B39]; [@B17]). Biphasic regulation of renal inflammation and NF-κB also appears important, where the first peak mediated through p65/p50 heterodimers induces inflammation through pro-inflammatory mediators such as MCP-1 and RANTES. The second peak on the other hand (p50/p50 homodimers) promotes resolution by downregulating MCP-1/CCL1, RANTES/CCL5, and TNF-α ([@B101]), while inducing expression of pro-resolving IL-10 ([@B21]). Similarly, to other pathologies it also appears that the phenotype of Mφs is important in CKD ([@B151]; [@B141]). Whereas M1 Mφ are detrimental, the M2a and perhaps even more so the M2c phenotype is beneficial ([@B153]).

Mφs play an important role in DN as previously reported by [@B144], [@B145]. Mφs increase production of ROS, pro-inflammatory cytokines, and pro-fibrotic growth factors that contribute to the formation of myo-fibroblasts. Mφs also appear to directly activate fibroblasts to a pro-fibrotic (myo-fibroblast) phenotype through secretion of galectin-3 ([@B52]). Inhibition of Mφ recruitment has been suggested to attenuate disease in several models of renal fibrosis with varying efficacy ([@B151]; [@B141]). For instance, MCP-1^--\ /\ --^ mice are protected against renal injury in a model of T1DM ([@B26]) and furthermore urinary levels of MCP-1 are predictive of renal injury in humans and have been proposed as a diagnostic marker of progressive diabetic kidney disease ([@B144]). There is a growing appreciation that the plasticity of Mφs is an important factor in disease progression ([@B35]; [@B153]) and that Mφs also contribute to the resolution of renal inflammation. For instance, Mφ efferocytosis of apoptotic cells is coupled to the generation of anti-inflammatory mediators such as IL-10 ([@B116]). To this effect, re-programming Mφs *ex vivo* toward a M2 phenotype (IL-4/IL-13 stimulation) provides protection in models of renal disease, whereas the M1 phenotype (LPS stimulation) is detrimental ([@B154]). Additional research suggests that M2a and M2c phenotypes are both renoprotective, but that the latter appears to be the more effective ([@B153]).

EXPERIMENTAL THERAPEUTICS AND DN
================================

Diabetic nephropathy is a chronic disease and current therapeutics primarily focus on glycemic and blood-pressure control through drugs targeting the renin--angiotensin system (RAS), such as angiotensin-converting-enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). However, these treatment regimes only slow the progression of the disease, but do not halt or reverse it. Furthermore, prolonged use of RAS inhibitors may induce hyperkalemia, reduction in systemic blood pressure and decreased renal blood flow. Therefore, there is a profound need for novel therapeutic strategies in this field and the search is ongoing ([@B31]; [@B135]). Examples of experimental therapeutics that show potential include bardoxolone methyl, which in clinical trials increases estimated glomerular filtration rate (eGFR) and creatinine clearance, while inhibiting inflammation in diabetic patients with stage 3b-4 CKD ([@B105],[@B106]; [@B146]). Pirfenidone is an oral anti-fibrotic and anti-inflammatory agent which shows therapeutic potential in DN, although it was initially developed for treatment of idiopathic pulmonary fibrosis. In a randomized, double blind study pirfenidone increased eGFR and decreased markers of inflammation (TNF, INF-γ, and IL-1; [@B134]) and has also demonstrated anti-fibrotic potential in both *in vitro* ([@B53]) and *in vivo* ([@B112]; [@B143]) models of renal disease. Vitamin D analogs, e.g., paricalcitol, may also be renoprotective agents through negatively regulating the RAS system and attenuation of renal fibrosis in rodent unilateral ureteric obstruction (UUO) models inhibiting accumulation of ECM as well as TGF-β1 and MCP-1 gene expression signaling ([@B76]; [@B77]). Vitamin D analogs have also been suggested to prevent podocyte injury by promoting expression of slit diaphragm proteins ([@B78]) and shows promising potential in emerging clinical trials reducing proteinuria in CKD patients ([@B77]).

As inflammation is a common denominator in CKD and a hallmark of DN, pro-resolving therapeutics may have potential benefit. We recently reported that LXs are protective in CKD, as pre-treatment with LXA~4~ and benzo-LXA~4~ modulates inflammation and fibrosis in early UUO-induced injury ([@B15]). UUO is an established model of progressive tubulointerstitial fibrosis and inflammation, relevant to CKD of diverse etiologies, including DN. UUO induces marked Mφ infiltration, tubular cell death, fibroblast activation, and possible phenotypic transition of resident renal cells characteristic of progressive renal fibrosis ([@B54]; [@B23]). Benzo-LXA~4~ and LXA~4~ attenuated UUO-induced fibrotic responses such as collagen accumulation by inhibiting collagen-1α2 gene expression, expression of collagen chaperone HSP47 and TGF-β1 signaling pathways ([@B15]). Interestingly, RvD1 has also been demonstrated to attenuate collagen deposition in a murine model of renal ischemia reperfusion ([@B36]). Specifically, LXs inhibited UUO-induced TGF-β1 canonical (Smad2) and non-canonical (Akt, Erk, and p38MAPK) signaling pathways, translating to reduced pro-fibrotic signaling ([@B15]). Although LXA~4~ did not alter the expression of TGF-β1, it did inhibit expression of MMP2 and CTGF. This is indeed noteworthy since MMP2 activates latent TGF-β1 and is a major driver of TGF-β1-mediated fibrosis. The LXA~4~ mediated reduction of CTGF, both at mRNA and protein levels, would likely result in reduced fibrotic responses. The anti-fibrotic effect of LXs has been demonstrated in several *in vitro* systems, inhibiting proliferation and cell cycle progression in mesangial cells ([@B17]). Recent data also demonstrate protection by RvE and RvD in murine UUO ([@B111]). LXs also appeared to shift Mφ phenotype and displayed significant pro-resolving actions in UUO-induced CKD. Whereas the total number of Mφ and MCP-1 remained unaltered, LX treated animals displayed decreased pro-inflammatory IFN-γ and TNF-α cytokines and increased pro-resolving IL-10 levels ([@B15]). Indeed, it appeared that the LXs induced a shift the Mφ phenotype toward an early stage M2c reparative phenotype, based on the high IL-10 expression induced by benzo-LXA~4~, although TGF-β1 remained unaffected ([@B15]).

Micro RNA (miRNA) may also prove an important therapeutic target in DN, as they have demonstrated importance in CKD pathogenesis ([@B61]; [@B152]; [@B79]). We recently reported that whereas TGF-β1 downregulates expression of the miRNA let-7c in renal epithelia, LXA~4~ enhances let-7c expression, and attenuates TGF-β1 fibrotic responses as let-7c targets expression of the TGF-βR1 (Brennan et al., in revision). Importantly, LXs inhibit ROS production ([@B17]; [@B16]; [@B160]), which may be analogous to the antioxidant effect of bardoxolone methyl ([@B118]). Indeed, bardoxolone methyl is an antioxidant inflammation modulator (AIM) compound, targeting Nrf2 which is a master regulator of the antioxidant response. Interestingly, LXA~4~ has been shown to inhibit LPS-mediated ROS production and to downregulate Nrf2 protein levels in human umbilical vein endothelial cells (HUVECs; [@B100]).

CONCLUSION
==========

Increasing evidence supports the role of chronic inflammation in the pathogenesis of T2DM and associated complications such as DN. Pro-resolving mediators, such as LXs, resolvins, and protectins, attenuate diabetes-related pathologies, including kidney disease and adipose inflammation. Thus promoting the resolution of inflammation through use of these lipids may provide a novel therapeutic strategy in the fight against diabetes-related pathologies.
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